Abbott Absorb bioresorbable stent

Abbott announced the initiation of the ABSORB III clinical trial in patients in the United States. The randomized controlled trial will enroll about 2,250 patients and compare the performance of Abbott's drug-eluting Absorb boresorbable vascular scaffold (BVS) device to the company's Xience family of drug-eluting stents.

 

At RSNA 2012, GE Healthcare announced a first-of-its-kind agreement with the University of Wisconsin (UW) School of Medicine and Public Health for the purpose of providing physicians with more tools to optimize radiation dose, take clinically-useful images, and potentially reduce the frequency of repeat computed tomography (CT) scans.

Biosensors International has announced enrollment of the first patient in LEADERS FREE, a clinical study involving BioFreedom, a polymer-free drug-coated stent (DCS) from Biosensors.

Fovia Medical Inc. and Blackford Analysis Ltd. announced plans to deliver compatible SDKs to the medical advanced visualization market.

Accumetrics Inc. announced that its next generation VerifyNow II System has achieved CE marking for point-of-care measurement of platelet reactivity to antiplatelet agents. This marks the culmination of a series of important milestones in 2012, increasing evidence of the clinical value of platelet reactivity testing and significantly expanding the market opportunities for the VerifyNow System in both surgical and interventional cardiology patient populations.

Biotronik announced that the European Heart Journal has published the clinical results of the ECOST trial (Effectiveness and Cost of ICD Follow-Up Schedule with Telecardiology). The randomized controlled study evaluated the safety and efficacy of Biotronik Home Monitoring compared with standard in-office follow-up visits for patients with implantable cardioverter-defibrillators (ICDs).

Subscribe to
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now